Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PF-05221304 Formulations in Healthy Adults
NCT03871439Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clesacostat in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Pfizer. Primary endpoints: Plasma PF-05221304 Area Under the Curve Last and Plasma PF-05221304 Maximum Concentration. Started Mar 2019; status: completed.
02
Drugs
clesacostat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03871439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871439.